Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02745678 · ClinicalTrials.gov registry record · Phase 1
Localized Therapeutics for the Treatment of Gastrointestinal Disorders II
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02745678: Completed Phase 1 study, sponsored by Stanford University.
NCT02745678 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02745678, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.
Primary Outcome
Using Modified Mayo Score
Interventions
- DRUG Thermosensitive gel rectal formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
What the finished NCT02745678 record still lists
NCT02745678 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Thermosensitive gel rectal formulation is the first listed.
NCT02745678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02745678 about?
NCT02745678 is a clinical study titled "Localized Therapeutics for the Treatment of Gastrointestinal Disorders II". The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.
What is the current status of trial NCT02745678?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2016-01. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02745678?
The interventions under investigation include: Thermosensitive gel rectal formulation (DRUG).
Who is sponsoring clinical trial NCT02745678?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02745678's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia